By Cecilia Butini

 

Sanofi SA said Monday that it has entered into an agreement to acquire U.K.-based biopharmaceutical company Kymab for an upfront payment of about $1.1 billion.

The French pharmaceutical major said the deal also includes the payment of up to $350 million upon achievement of certain milestones.

The acquisition of Kymab--which focuses on the development of fully human monoclonal antibodies--would give Sanofi full global rights to the KY1005 monoclonal antibody, it said. The antibody can be used in the treatment of a range of immune and inflammatory diseases, according to Sanofi.

The acquisition will be financed in cash and is expected to close in the first half of 2021, the company said.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

January 11, 2021 03:05 ET (08:05 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Sanofi Charts.